OPAD:NYSEOfferpad Solutions Inc. Analysis
Data as of 2026-04-22 - not real-time
$0.86
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Offerpad Solutions (OPAD) trades around $0.86, a price that is well below its DCF‑derived fair value of roughly $32 and the analyst consensus target of $1.75, yielding an implied upside of over 100% (undervalued on a price‑to‑book basis at 0.84×). The company’s revenue has contracted sharply (‑34.5% YoY) and margins remain negative, yet it generates positive operating cash flow ($66.8 M) and free cash flow ($117 M), indicating a cash‑rich business despite a heavy debt load (Debt/Equity ≈ 280). Technical signals are mixed: the 20‑day SMA (0.74) and 50‑day SMA (0.77) sit below the current price, the MACD histogram is bullish, and volume is rising, but the long‑term 200‑day SMA (1.92) remains far above price, reinforcing a bearish long‑term trend and a volatility of nearly 79% with a beta above 2.5.
The latest management commentary highlights a strategic pivot from a single‑product iBuyer model to a diversified platform that leverages generative AI (SCOUT and HENRY) to accelerate transaction velocity and reduce acquisition costs. Growth in the Brokerage Solutions division and the rollout of AI‑driven tools are designed to hit a 1,000‑transaction‑per‑quarter target and move the company toward profitability, providing a compelling growth narrative that could re‑price the stock if execution materializes.
The latest management commentary highlights a strategic pivot from a single‑product iBuyer model to a diversified platform that leverages generative AI (SCOUT and HENRY) to accelerate transaction velocity and reduce acquisition costs. Growth in the Brokerage Solutions division and the rollout of AI‑driven tools are designed to hit a 1,000‑transaction‑per‑quarter target and move the company toward profitability, providing a compelling growth narrative that could re‑price the stock if execution materializes.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Bullish MACD and rising volume suggest short‑term momentum
- Price is near the immediate resistance level of $0.90
- High volatility and negative earnings keep downside risk elevated
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Strategic AI integration aims to improve conversion and lower costs
- Positive cash flow and a large upside to the $1.75 target price
- Undervalued multiples (P/B 0.84×, P/S 0.07×) provide margin for appreciation
Long Term
> 3 yearsPositive
Model confidence: 6/10
Key Factors
- Potential turnaround to profitability through diversified platform
- DCF fair value suggests a multi‑digit upside if growth targets are met
- High beta offers amplified returns for investors willing to accept risk
Key Metrics & Analysis
Financial Health
Revenue Growth-34.50%
Profit Margin-8.17%
P/E Ratio-3.0
ROE-108.03%
ROA-8.92%
Debt/Equity279.79
P/B Ratio0.8
Op. Cash Flow$66.8M
Free Cash Flow$117.2M
Industry P/E33.2
Technical Analysis
TrendBearish
RSI61.1
Support$0.57
Resistance$0.90
MA 20$0.74
MA 50$0.77
MA 200$1.92
MACDBullish
VolumeIncreasing
Fear & Greed Index86.71
Valuation
Fair Value$32.01
Target Price$1.75
Upside/Downside103.80%
GradeUndervalued
TypeBlend
Risk Assessment
Beta2.78
Volatility78.86%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.